Compare ACU & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | MDWD |
|---|---|---|
| Founded | 1867 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 181.1M |
| IPO Year | 1994 | 2013 |
| Metric | ACU | MDWD |
|---|---|---|
| Price | $47.56 | $14.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $36.00 |
| AVG Volume (30 Days) | 15.0K | ★ 80.3K |
| Earning Date | 04-23-2026 | 05-20-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 1.63 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $196,541,816.00 | N/A |
| Revenue This Year | $5.67 | $48.92 |
| Revenue Next Year | $5.25 | $35.04 |
| P/E Ratio | $196.63 | ★ N/A |
| Revenue Growth | ★ 1.05 | N/A |
| 52 Week Low | $35.50 | $13.54 |
| 52 Week High | $50.00 | $21.11 |
| Indicator | ACU | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 48.94 |
| Support Level | $43.36 | $13.65 |
| Resistance Level | $50.00 | $15.18 |
| Average True Range (ATR) | 1.44 | 0.51 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 75.33 | 42.03 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.